CoDa Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs in inflammation, wound-healing and tissue repair. The company is pioneering a new field of science known as gap junction modulation, using a new class of therapeutics that can modulate wound responses and reduce inflammation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/25/12 | $20,000,000 | Series B |
BioPacificVentures Domain Associates GBS Venture Partners RusnanoMedInvest | undisclosed |
